Interestingly, targeted therapies for metastatic melanoma using BRAF inhibitors, such as vemurafenib and dabrafenib that block the active conformation of the BRAF kinase, are associated with a higher risk of cSCC development [27,28]. Here, BRAF is linked to metastatic melanoma.